{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:56:13Z","timestamp":1791244573296,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.eclinm.2024.102733","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T21:08:39Z","timestamp":1721336919000},"page":"102733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B"],"prefix":"10.1016","volume":"74","author":[{"given":"Alexander","family":"R\u00f6th","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigbj\u00f8rn","family":"Berentsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Jilma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene C.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine M.I.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Storek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Jayawardene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Ward\u0119cki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Broome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eclinm.2024.102733_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/hemato3010014","article-title":"Cold agglutinin disease: a distinct clonal B-cell lymphoproliferative disorder of the bone marrow","volume":"3","author":"Climent","year":"2022","journal-title":"Hemato"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102733_bib2","first-page":"35","article-title":"Cold agglutinin disease: where do we stand, and where are we going?","volume":"18","author":"Berentsen","year":"2020","journal-title":"Clin Adv Hematol Oncol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102733_bib3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2013-02-474437","article-title":"Cold agglutinin disease","volume":"122","author":"Swiecicki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.eclinm.2024.102733_bib4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102733_bib5","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102733_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/asheducation-2016.1.226","article-title":"Cold agglutinin disease","volume":"2016","author":"Berentsen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"13","key":"10.1016\/j.eclinm.2024.102733_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/bloodadvances.2017004390","article-title":"Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization","volume":"1","author":"Mullins","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.eclinm.2024.102733_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/10245330701445392","article-title":"Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy","volume":"12","author":"Berentsen","year":"2007","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102733_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/trf.16745","article-title":"Complement-mediated hemolysis persists year round in patients with cold agglutinin disease","volume":"62","author":"R\u00f6th","year":"2022","journal-title":"Transfusion"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2024.102733_bib10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V130.Suppl_1.928.928","article-title":"Incidence of thromboembolic events is increased in a retrospective analysis of a large cold agglutinin disease (CAD) cohort","volume":"130","author":"Broome","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102733_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2018-06-856930","article-title":"Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial","volume":"133","author":"J\u00e4ger","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102733_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A\u00a0randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bartko","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.eclinm.2024.102733_bib13","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"R\u00f6th","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102733_bib17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1007\/s00277-022-04948-y","article-title":"Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study","volume":"101","author":"R\u00f6th","year":"2022","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.eclinm.2024.102733_bib18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/ajh.26965","article-title":"Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease","volume":"98","author":"R\u00f6th","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.eclinm.2024.102733_bib19","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"R\u00f6th","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102733_bib20","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ejh.13903","article-title":"Sutimlimab provides clinically meaningful improvements in patient-reported outcomes in patients with cold agglutinin disease: results from the randomised, placebo-controlled, Phase 3 CADENZA study","volume":"110","author":"R\u00f6th","year":"2023","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.eclinm.2024.102733_bib21","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3324\/haematol.2021.279812","article-title":"Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results","volume":"107","author":"Roth","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.eclinm.2024.102733_bib22","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/bloodadvances.2019001321","article-title":"Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program","volume":"4","author":"Gelbenegger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.eclinm.2024.102733_bib23","series-title":"Biochemistry, lactate dehydrogenase","author":"Farhana","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102733_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.eclinm.2024.102733_bib25","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.eclinm.2024.102733_bib26","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1182\/blood-2010-06-288647","article-title":"High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease","volume":"116","author":"Berentsen","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.eclinm.2024.102733_bib27","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024003122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T23:47:55Z","timestamp":1728431275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024003122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":24,"alternative-id":["S2589537024003122"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102733","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102732","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102733"}}